We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+0.05%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$3.55B
AUM Growth
+$59.4M
Cap. Flow
+$77M
Cap. Flow %
2.17%
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128

Top Buys

Rank Stock Value
1
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$138M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$131M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$127M
4
MRO
Marathon Oil Corporation
MRO
+$123M
5
CHX
ChampionX
CHX
+$98.3M

Top Sells

Rank Stock Value
1
PXD
Pioneer Natural Resource Co.
PXD
+$638M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$51.2M
3
DFS
Discover Financial Services
DFS
+$45.1M
4
SCRM
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
+$18.4M
5
NSC icon
Norfolk Southern
NSC
+$17.7M

Sector Composition

Rank Sector Weight
1 Energy 26.53%
2 Technology 21.03%
3 Healthcare 14.68%
4 Industrials 8.19%
5 Materials 6.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
226
Praxis Precision Medicines
PRAX
$10.3B
$1.48M 0.04%
35,729
+1,000
+3% +$47.3K
SLN
227
Silence Therapeutics
SLN
$554M
$1.46M 0.04%
76,840
+4,617
+6% +$98.2K
COHR icon
228
Coherent
COHR
$65.4B
$1.45M 0.04%
20,000
-17,069
-46% -$1.03M
KALV
229
DELISTED
KalVista Pharmaceuticals
KALV
$1.45M 0.04%
122,960
+40,960
+50% +$478K
WEL
230
DELISTED
Integrated Wellness Acquisition Corp
WEL
$1.45M 0.04%
125,054
– –
RARE icon
231
Ultragenyx Pharmaceutical
RARE
$2.55B
$1.44M 0.04%
35,128
-7,478
-18% -$319K
BAX icon
232
Baxter International
BAX
$14B
$1.44M 0.04%
43,126
-43,000
-50% -$1.58M
SYRS
233
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.44M 0.04%
278,103
+103,103
+59% +$542K
VERA icon
234
Vera Therapeutics
VERA
$2.3B
$1.43M 0.04%
39,416
+11,850
+43% +$470K
TMCI icon
235
Treace Medical Concepts
TMCI
$284M
$1.42M 0.04%
212,976
+77,063
+57% +$623K
BDTX icon
236
Black Diamond Therapeutics
BDTX
$110M
$1.42M 0.04%
303,706
+46,706
+18% +$251K
LBPH
237
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$1.39M 0.04%
51,596
-2,457
-5% -$48.5K
QCOM icon
238
Qualcomm
QCOM
$168B
$1.39M 0.04%
7,000
-8,500
-55% -$1.61M
IAS
239
DELISTED
Integral Ad Science
IAS
$1.39M 0.04%
+142,500
New +$1.36M
KIDS icon
240
OrthoPediatrics
KIDS
$596M
$1.38M 0.04%
48,097
-16,717
-26% -$512K
IMCR icon
241
Immunocore
IMCR
$1.75B
$1.36M 0.04%
40,014
+11,090
+38% +$566K
WMT icon
242
Walmart Inc
WMT
$892B
$1.35M 0.04%
+20,000
New +$1.26M
NFYS
243
DELISTED
Enphys Acquisition Corp.
NFYS
$1.35M 0.04%
122,826
– –
IQV icon
244
IQVIA
IQV
$38.3B
$1.34M 0.04%
+6,316
New +$1.43M
MNSO icon
245
MINISO
MNSO
$3.75B
$1.33M 0.04%
+69,980
New +$1.54M
ROIV icon
246
Roivant Sciences
ROIV
$25.4B
$1.31M 0.04%
124,217
+27,000
+28% +$296K
MIRM icon
247
Mirum Pharmaceuticals
MIRM
$5.74B
$1.3M 0.04%
38,088
-11,769
-24% -$309K
NKTR icon
248
Nektar Therapeutics
NKTR
$2.48B
$1.29M 0.04%
69,595
+7,220
+12% +$152K
AGIO icon
249
Agios Pharmaceuticals
AGIO
$1.91B
$1.29M 0.04%
30,013
-49,893
-62% -$1.8M
ESTA icon
250
Establishment Labs
ESTA
$2.33B
$1.29M 0.04%
28,445
-10,000
-26% -$507K
8 9
10
11 12

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return

UBS O'Connor's Q2 2024 Portfolio in Review

As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.

By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.

  • UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
  • UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
  • UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
  • UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
  • UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
  • UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
  • UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.